UNC scientists receive grant to develop targeted delivery system for pancreatic cancer

NewsGuard 100/100 Score

A team of UNC scientists has received a five-year $2,308,800 grant from the National Cancer Institute's Cancer Nanotechnology Platform Partnerships to address the critical need for early diagnosis of and more effective treatments for pancreatic cancer.

Wenbin Lin, PhD, professor of chemistry and pharmacy, and Jen Jen Yeh, MD, assistant professor of surgery and pharmacology, are the principal investigators. Leaf Huang, PhD, Fred N. Eshelman Distinguished Professor and chair of molecular pharmaceutics in the UNC Eshelman School of Pharmacy, is the co-investigator. All are members of UNC Lineberger Comprehensive Cancer Center, and Lin is a faculty member in the UNC College of Arts and Sciences.

Using targeted nano-particle technology, based on nano-materials developed in the Lin lab, the scientists will design nanoscale metal-organic frameworks -a new class of hybrid nano-materials- capable of carrying both imaging and therapeutic cargoes or multiple drugs to increase therapeutic effect. The efficacy of these nano-materials will be evaluated in pre-clinical work by Yeh. Huang will help to modify the pharmcokinetics of the nano-materials.

"Pancreatic cancer is difficult to detect early and to treat," says Lin. " By developing a more targeted delivery system for imaging, we hope to be able to detect tumors earlier. And by using the hybrid nano-materials to deliver drugs directly to the tumor, we could lessen side effects for patients.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery